Small-molecule genetic medicine:

One GeneSTITCH™ at a time

Weaver’s novel platform unlocks an untapped frontier in medicine: direct, sequence-specific gene activation using small molecules.

Therapeutic Focus

Weaver’s GeneSTITCH™ molecules act directly at the fetal hemoglobin gene locus to selectively activate its expression

Sickle Cell
Disease

Lead indication; clinically validated MoA

~120K

ADDRESSABLE
PATIENTS

Weaver is advancing a disease-modifying approach for a severe inherited kidney disease with limited treatment options. By acting directly at the disease gene locus, our programmable GeneSTITCH™ molecules restore expression of a critical therapeutic protein.

Renal

Functional protein
rescue;
mutation-agnostic

~130K

ADDRESSABLE
PATIENTS

Weaver has a fundamentally different approach to cardiovascular disease. Our programmable GeneSTITCH™ molecules selectively restore expression of a cholesterol-clearing protein to address atherosclerosis at its biological source.

Cardiovascular

In situ atheroma reduction

>1M

ADDRESSABLE
PATIENTS

Science

OUR TECHNOLOGY

Small molecules that deliver the therapeutic impact of genetic medicines.

Our proprietary GeneSTITCH™ platform utilizes bifunctional small molecules to selectively bind target genes and recruit transcriptional modulators. We deliver the profound therapeutic impact of targeted gene activation through familiar, scalable small molecule pharmacology.

By combining the precision of genetic medicines with the convenience of small molecule drugs, our modular platform expands the druggable genome through three core components:

1

PROGRAMMABLE BINDERS

Built on advanced polyamide chemistry, these highly selective molecules target specific DNA sequences, unlocking disease-driving genes that were previously considered undruggable.

2

NOVEL LINKERS

Proprietary chemistries that seamlessly connect the platform's components, optimized to deliver excellent cell permeability and ideal drug-like properties.